BriaCell Therapeutics Corp. 8-K

What Happened

• BriaCell Therapeutics Corp. filed an 8-K on March 9, 2026 reporting the results of its Annual General and Special Meeting of Shareholders. The record date for voting was January 26, 2026; 7,250,487 common shares were outstanding and 3,502,695 shares were represented at the meeting (quorum).
• Shareholders ratified the appointment of MNP LLP as auditors, elected six director nominees, and re-approved the Company’s omnibus equity incentive plan. Vote totals reported by proposal:
  • Auditor ratification (MNP LLP): For 3,431,761; Withhold 70,934; Broker Non-Votes 0.
  • Directors elected (each to serve until the next annual meeting):
    • Dr. Jane Gross — For 1,837,220; Withhold 49,810; Broker Non-Votes 1,615,665
    • Mr. Jamieson Bondarenko — For 1,847,842; Withhold 39,188; Broker Non-Votes 1,615,665
    • Dr. William V. Williams — For 1,837,675; Withhold 49,355; Broker Non-Votes 1,615,665
    • Dr. Rebecca Taub — For 1,837,729; Withhold 49,301; Broker Non-Votes 1,615,665
    • Mr. Vaughn C. Embro-Pantalony — For 1,847,644; Withhold 39,386; Broker Non-Votes 1,615,665
    • Mr. Martin Schmieg — For 1,844,132; Withhold 42,898; Broker Non-Votes 1,615,665
  • Omnibus Equity Incentive Plan re-approval: For 1,524,081; Against 362,949; Broker Non-Votes 1,615,665
• The Omnibus Equity Incentive Plan is incorporated by reference (Exhibit 10.1 per the filing).

Key Details

• Shares outstanding (record date): 7,250,487; shares represented at meeting: 3,502,695 (quorum).
• Auditors: MNP LLP ratified — For 3,431,761; Withhold 70,934.
• All six director nominees were elected; individual “For” votes ranged ~1.837M–1.848M with ~1.616M broker non-votes on director votes.
• Omnibus Equity Incentive Plan re-approved: For 1,524,081; Against 362,949; Broker Non-Votes 1,615,665.

Why It Matters

• Board and governance: The election of all six nominees confirms the company’s board composition through the next annual meeting, which affects oversight and corporate strategy.
• Corporate actions enabled: Re-approval of the Omnibus Equity Incentive Plan allows the company to continue granting equity awards (shares/options) under that plan, which can affect future dilution and employee incentives.
• Auditor continuity: Ratification of MNP LLP maintains continuity in external audit oversight.
• Voting context: A substantial number of broker non-votes were recorded on director and equity-plan matters (1,615,665), which is a material voting block when assessing shareholder participation on certain proposals.